

## Special Issue

# Advances in Oral and Oropharyngeal Cancer: From Translational Research to Clinical Practice

### Message from the Guest Editors

Oral and oropharyngeal cancers still represent a challenge because of different etiologies (smoke, alcohol, and human papillomavirus) and carcinogenesis. Flap reconstruction and transoral robotic surgery facilitate better functional results, while de-escalation trails have been performed for HPV-related oropharyngeal tumors. However, the recurrence rate and mortality did not decrease in recent years. Furthermore, despite the emerging role of immunotherapy for recurrent/metastatic cancer, the treatment of advanced tumors remains challenging. This Special Issue aims to highlight the current state of the art and describe future perspectives for the management of oral and oropharyngeal cancer. In particular, original articles and reviews from translational research to clinical practice are welcome. We look forward to receiving your contributions.

### Guest Editors

Prof. Dr. Giancarlo Pecorari

Division of Otorhinolaryngology, Department of Surgical Sciences, University of Turin, 10126 Torino, Italy

Dr. Giuseppe Riva

Department of Surgical Sciences, University of Turin, 10126 Torino, Italy

### Deadline for manuscript submissions

closed (30 September 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/139556](https://mdpi.com/si/139556)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)